Skip to main content

Table 1 Cohort characteristics

From: Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

Overall n689
BMI (mean (sd))27.76 (6.62)
Age (mean (sd))62.27 (13.21)
Sex = Male (%)402 (58.3)
ECOG (%)
 0185 (31.0)
 1272 (45.6)
 2113 (19.0)
  > 226 (4.4)
CCI = 0–1 (%)458 (66.7)
Cancer (%)
 Bladder Cancer32 (4.9)
 Head and Neck Carcinoma42 (6.5)
 Melanoma184 (28.4)
 Non-Small Cell Lung Cancer152 (23.5)
 Renal Cell Carcinoma65 (10.0)
 Sarcoma21 (3.2)
 Other152 (23.5)
Staging (%)
 11 (0.2)
 24 (0.7)
 344 (7.2)
 4547 (90.0)
 Unknown12 (2.0)
Immune Checkpoint Inhibitors (%)
 Atezolizumab22 (3.2)
 Durvalumab12 (1.7)
 Durva + Tremelimumab6 (0.9)
 Ipilimumab126 (18.3)
 Nivolumab364 (52.8)
 Nivolumab + Ipilimumab37 (5.4)
 Pembrolizumab104 (15.1)
 Tremelimumab3 (0.4)
 Other15 (2.2)
ATB within 28 days of ICI (%)241 (35.0)
CS within 28 days of ICI (%)273 (39.6)